Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

PENG vs PHPB for analgetika ved hofteartroplastikk

10. november 2026 oppdatert av: Ankara City Hospital Bilkent

Postoperativ analgesisk effektivitet av Pericapsular Nerve Block (PENG) og Posterior Hip Pericapsular Block (PHPB) ved hofteartroplastikk

Total hip arthroplasty (THA) is a commonly performed surgical procedure, and its incidence continues to rise with the aging population. Effective postoperative analgesia facilitates early mobilization and accelerates recovery. The pericapsular nerve group (PENG) block provides analgesia to the anterior hip capsule by targeting the articular branches of the femoral, obturator, and accessory obturator nerves. However, due to the contribution of sacral plexus-derived nerves (quadratus femoris, superior gluteal, and inferior gluteal nerves) to posterior hip pain, anterior blocks alone may be insufficient.

This prospective study aims to compare the efficacy of preoperatively administered PENG block alone versus the combination of PENG and posterior hip pericapsular block (PHPB) in postoperative pain control after total hip arthroplasty. The primary outcome is postoperative pain intensity assessed by the Numerical Rating Scale (NRS). Secondary outcomes include the Quality of Recovery score (QoR-15), opioid consumption, manual muscle testing (MMT) results, time to mobilization, and block-related complications.

Studieoversikt

Detaljert beskrivelse

Total hip arthroplasty (THA) is a widely performed surgical procedure, and its incidence continues to increase with the aging population. It is an effective intervention to improve the quality of life in patients with advanced osteoarthritis or rheumatoid arthritis. Postoperative pain is one of the most common complications following THA. Effective postoperative analgesia facilitates early mobilization and accelerates recovery. Early mobilization within the first 24 hours after surgery has been shown to significantly reduce the length of hospital stay.

Regional anesthesia techniques for postoperative analgesia in hip surgery play a crucial role in pain management and recovery. International pain management guidelines recommend multimodal analgesic protocols for elective total hip arthroplasty, emphasizing the role of peripheral nerve blocks as part of these strategies.

Current anatomical studies have demonstrated that the innervation of the hip joint capsule is derived from multiple nerves originating from the lumbosacral plexus. The density and distribution of this neural supply may vary among individuals depending on pelvic morphology, ethnicity, and sex. The anterior portion of the hip joint capsule is primarily innervated by articular branches of the femoral and obturator nerves, while the posterior aspect receives innervation from branches of the sciatic nerve, the superior gluteal nerve, and the nerve to quadratus femoris (NQF). The NQF, which provides significant sensory input to the posterior hip region, has become a key anatomical target for posterior hip-focused regional anesthesia techniques.

The pericapsular nerve group (PENG) block, first described by Girón-Arango et al., provides analgesia to the anterior hip capsule by blocking the articular branches of the femoral, obturator, and accessory obturator nerves. PENG block has been suggested to facilitate early mobilization and recovery compared to other anterior approaches. However, even with appropriate anterior blocks, posterior gluteal pain may persist in patients with hip pathology. This highlights the potential importance of targeting sacral plexus-derived nerves for comprehensive analgesia.

Recent research has shown that branches from the quadratus femoris nerve (NQF), superior gluteal nerve (SGN), and inferior gluteal nerve (IGN) contribute to the posterior capsule innervation of the hip joint. Regional anesthesia techniques targeting these posterior articular branches may enhance postoperative analgesia, promote early mobilization, and improve functional recovery. Consequently, the integration of sacral plexus-focused posterior blocks alongside anterior approaches is increasingly being emphasized in multimodal analgesia protocols for THA.

The combination of the posterior hip pericapsular block (PHPB) with the PENG block has been reported to provide balanced and effective analgesia across the entire hip capsule while preserving motor function.

The aim of this prospective study is to compare the efficacy of preoperatively administered PENG block alone versus the combination of PENG and posterior hip pericapsular block (PHPB) for postoperative pain control in patients undergoing total hip arthroplasty. The primary endpoint is postoperative pain intensity assessed using the Numerical Rating Scale (NRS). Secondary endpoints include the Quality of Recovery (QoR-15) score, opioid consumption, manual muscle testing (MMT) results, time to mobilization, and block-related complications.

Studietype

Observasjonsmessig

Registrering (Faktiske)

127

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Çankaya
      • Ankara, Çankaya, Tyrkia (Türkiye), 06800
        • Ankara Bilkent City Hospital Departmant of Anesthesiology and Reanimation, Ankara,Çankaya

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Adult patients aged 18 years and older, classified as ASA physical status I-II, scheduled for elective total hip arthroplasty under spinal anesthesia at Ankara Bilkent City Hospital. A total of 132 patients who meet the inclusion criteria and provide written informed consent will be enrolled in this single-center, prospective, randomized controlled trial.

Beskrivelse

Inclusion Criteria:

  • Patients scheduled for elective total hip arthroplasty (THA) under spinal anesthesia
  • ASA physical status I-II
  • Age ≥18 years
  • Body Mass Index (BMI) between 18-35 kg/m²
  • Patients who provide written informed consent

Exclusion Criteria:

  • Age <18 years
  • ASA physical status ≥III
  • Known allergy or contraindication to study medications (local anesthetics, opioids, etc.)
  • Severe cardiac, renal, hepatic, or pulmonary failure
  • Revision total hip arthroplasty
  • Coagulopathy or anticoagulant use
  • Local infection or neuropathic findings at the injection site
  • Chronic inflammatory diseases or chronic corticosteroid use
  • Diagnosed neuropsychiatric disorders
  • Pregnancy or lactation
  • Inability or unwillingness to read, understand, or sign the informed consent form
  • Obesity (BMI >35 kg/m²)
  • Failed spinal anesthesia or conversion to general anesthesia
  • Active malignancy or patients receiving radiotherapy/chemotherapy
  • Active systemic infection or ongoing antibiotic therapy (except prophylaxis)
  • Contraindication to regional anesthesia techniques
  • Chronic opioid or analgesic use for pain disorders
  • History of intracranial mass, increased intracranial pressure, epilepsy, cerebrovascular accident, neuromuscular disease, or motor/sensory deficits

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: CASE_CONTROL
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
PENG Group

The group that will receive the preoperative Pericapsular Nerve Group (PENG) block

Patients in this group will also undergo elective total hip arthroplasty (THA) under spinal anesthesia.A preoperative Pericapsular Nerve Group (PENG) block will be performed under ultrasound guidance using 20 mL of 0.25% bupivacaine. The injection will be administered between the psoas tendon and the iliac bone to block the articular branches of the femoral, obturator, and accessory obturator nerves, providing analgesia to the anterior hip capsule.

PENG + PHPB Group

The group that will receive the preoperative Pericapsular Nerve Group (PENG) block and Posterior Hip Pericapsular Block (PHPB)

Patients in this group will also undergo elective total hip arthroplasty (THA) under spinal anesthesia.A preoperative Pericapsular Nerve Group (PENG) block will be performed under ultrasound guidance using 20 mL of 0.25% bupivacaine. The injection will be administered between the psoas tendon and the iliac bone to block the articular branches of the femoral, obturator, and accessory obturator nerves, providing analgesia to the anterior hip capsule. In addition to the PENG block, a Posterior Hip Pericapsular Block (PHPB) will be performed under ultrasound guidance using 20 mL of 0.25% bupivacaine. The local anesthetic will be injected between the piriformis muscle and the ischiofemoral ligament to target the posterior articular branches of the quadratus femoris, superior gluteal, and inferior gluteal nerves. The combined PENG + PHPB approach aims to provide comprehensive analgesia of both the anterior and posterior hip capsule while preserving motor function.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Postoperative pain
Tidsramme: Up to 48 hours postoperatively

Postoperative pain will be assessed using the Numeric Rating Scale (NRS; 0 = no pain, 10 = worst imaginable pain) at rest and during movement at 0, 2, 6, 8, 12, 24, 36, and 48 hours after surgery. The NRS scores will be compared between the two study groups (PENG vs. PENG + PHPB) to evaluate the effectiveness of the blocks in postoperative analgesia following total hip arthroplasty.

Up to 48 hours postoperatively

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
QUALİTY OF RECOVERY-15
Tidsramme: Preoperative, 24, and 48 hours postoperatively

The quality of postoperative recovery will be assessed using the validated 15-item Quality of Recovery questionnaire (QoR-15). The total score ranges from 0 (very poor recovery) to 150 (excellent recovery). The score will be measured preoperatively and at 24 and 48 hours postoperatively to compare recovery quality between the two groups.

Preoperative, 24, and 48 hours postoperatively
MANUEL MUSCLE TEST
Tidsramme: 6, 12, and 24 hours postoperatively

Quadriceps muscle strength will be evaluated using the Manual Muscle Test (MMT) scale at 6, 12, and 24 hours after surgery. The MMT scale ranges from 0 (no contraction) to 5 (normal strength). A score <3 indicates quadriceps weakness.

6, 12, and 24 hours postoperatively
Rescue analgesic
Tidsramme: 0-48 hours postoperatively

The time from the end of surgery to the patient's first request for rescue analgesia will be recorded. Rescue analgesia consists of intravenous tramadol 100 mg administered if the Numeric Rating Scale (NRS) score is ≥ 4. This measure will compare the analgesic duration provided by the two blocks (PENG vs. PENG + PHPB).

0-48 hours postoperatively
Postoperative Nausea and Vomiting (PONV)
Tidsramme: 0-48 hours postoperatively

The presence of postoperative nausea and/or vomiting will be recorded during the first 48 hours following surgery.

0-48 hours postoperatively
Length of Hospital Stay
Tidsramme: Up to discharge (approximately 3-5 days postoperatively)

The duration of hospitalization will be measured from the day of surgery to discharge.

Up to discharge (approximately 3-5 days postoperatively)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Abdulkadir But, Professor, Ankara Bilkent City Hospital Departmant of Anesthesiology and Reanimation,Ankara,Çankaya

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. desember 2025

Primær fullføring (Faktiske)

15. april 2026

Studiet fullført (Faktiske)

1. juli 2026

Datoer for studieregistrering

Først innsendt

24. november 2025

Først innsendt som oppfylte QC-kriteriene

24. november 2025

Først lagt ut (Faktiske)

4. desember 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. november 2026

Sist bekreftet

1. oktober 2025

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • E2-25-12993

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere